Cargando…

Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study

BACKGROUND: Cebranopadol is a nociceptin/orphanin FQ peptide/opioid receptor agonist with central antinociceptive activity. We hypothesize that this novel mechanism of action may lead to a lower risk of abuse compared with pure μ-opioid peptide receptor agonists. METHODS: We conducted a single-dose,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Göhler, Karin, Sokolowska, Marta, Schoedel, Kerri A., Nemeth, Robert, Kleideiter, Elke, Szeto, Isabella, Eerdekens, Marie-Henriette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319565/ https://www.ncbi.nlm.nih.gov/pubmed/30531478 http://dx.doi.org/10.1097/JCP.0000000000000995

Ejemplares similares

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Bond, Mary, et al.
Publicado: (2018)

Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic
por: Kleideiter, Elke, et al.
Publicado: (2017)

Correction to: Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic
por: Kleideiter, Elke, et al.
Publicado: (2018)

Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users
por: Colucci, Salvatore V., et al.
Publicado: (2014)

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Darwish, Mona, et al.
Publicado: (2017)

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
por: Setnik, Beatrice, et al.
Publicado: (2017)

Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users
por: Raofi, Saeid, et al.
Publicado: (2021)

Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users
por: Webster, Lynn R, et al.
Publicado: (2012)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users
por: Webster, Lynn R., et al.
Publicado: (2017)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users
por: Smith, Michael D., et al.
Publicado: (2017)

Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial
por: Christoph, Annette, et al.
Publicado: (2017)

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors
por: Shen, Qianwei, et al.
Publicado: (2017)

Impact of Intravenous Naltrexone on Intravenous Morphine-Induced High, Drug Liking, and Euphoric Effects in Experienced, Nondependent Male Opioid Users
por: Webster, Lynn R., et al.
Publicado: (2012)

Abuse potential of mirogabalin in recreational polydrug users
por: Mendell, Jeanne, et al.
Publicado: (2019)

Recreation without Damnation
por: Pratt, Ben. H.
Publicado: (1875)

Evaluation of the abuse potential of difelikefalin, a selective kappa‐opioid receptor agonist, in recreational polydrug users
por: Shram, Megan J., et al.
Publicado: (2021)

Cebranopadol as a Novel Promising Agent for the Treatment of Pain
por: Ziemichod, Wojciech, et al.
Publicado: (2022)

Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist
por: Rizzi, Anna, et al.
Publicado: (2016)

Where Shall We Recreate and How?
por: Pratt, Ben. H.
Publicado: (1880)

Effects of Cebranopadol on Cocaine-induced Hyperactivity and Cocaine Pharmacokinetics in Rats
por: Wei, Huimei, et al.
Publicado: (2020)

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users
por: Harris, Stephen C, et al.
Publicado: (2014)

Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model
por: Christoph, Thomas, et al.
Publicado: (2018)

Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects
por: Webster, Lynn R., et al.
Publicado: (2018)

Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2016)

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2017)

Cebranopadol: A First-in-Class Nociceptin Receptor Agonist for Managing Chronic Pain
por: Nair, Abhijit S, et al.
Publicado: (2020)

Abuses of the Stomach: Or, the Need of Cibarious Reform
por: Pratt, Ben. H.
Publicado: (1878)

US study of gliding in nondependent lung regions: the dark side of the moon
por: De Blasio, E, et al.
Publicado: (2014)

Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain
por: Sałat, Kinga, et al.
Publicado: (2017)

No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial
por: Seifritz, Erich, et al.
Publicado: (2020)

The impact of recreational marijuana commercialization on traumatic injury
por: Chung, Christine, et al.
Publicado: (2019)

Alveolar instability caused by mechanical ventilation initially damages the nondependent normal lung
por: Pavone, Lucio, et al.
Publicado: (2007)

Differentiation of acid-ph-dependent and -nondependent entry pathways for mouse hepatitis virus
por: Kooi, Cora, et al.
Publicado: (1991)

A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism
por: Fantinati, Anna, et al.
Publicado: (2017)

ELDER ABUSE AND THE OPIOID CRISIS: PERPETRATORS WHO ARE SUBSTANCE USERS
por: Roberto, Karen A, et al.
Publicado: (2019)

Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data
por: Schoedel, Kerri A., et al.
Publicado: (2021)

Androgen Abuse among Recreational Athletes
por: Araujo, Maíta Poli de
Publicado: (2019)

Interrupted Time Series of User‐centered Clinical Decision Support Implementation for Emergency Department–initiated Buprenorphine for Opioid Use Disorder
por: Holland, Wesley C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jp09hft22s28p6qq2r2bfqji4p